6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of May 2017

FRESENIUS MEDICAL CARE AG & Co. KGaA

(Translation of registrant’s name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

On May 3, 2017 Fresenius Medical Care AG & Co. KGaA (the “Company”) issued a Press Release announcing its first quarter results for the period ending March 31, 2017. A copy of the Press Release is furnished as Exhibit 99.1 and the corresponding financial figures as Exhibit 99.2.

The attached Press Release contains non-GAAP financial measures. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles. To supplement our first quarter 2017 consolidated financial results presented in accordance with International Financial Reporting Standards, or IFRS, we have used non-GAAP financial measure of (a) EBITDA, or operating income excluding interest, taxes, depreciation and amortization, (b) delivered operating income (earnings before interest and taxes), and (c) free cash flow. These non-GAAP measures are provided to enhance the user’s overall understanding of our current financial performance and our prospects for the future. In addition, because we have historically reported certain non-GAAP financial measures in our financial results, we believe the inclusion of these non-IFRS financial measures provides consistency and comparability in our financial reporting to prior periods for which these non-GAAP financial measures were previously reported. These non-GAAP financial measures should not be used as a substitute for or be considered superior to GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most comparable IFRS financial measures are included in the attached Press Release in a separate statement setting forth the reconciliation and in the Cash Flow Statement.

The Exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: May 3, 2017

FRESENIUS MEDICAL CARE AG & Co. KGaA, a partnership limited by shares, represented by:
FRESENIUS MEDICAL CARE MANAGEMENT AG, its General Partner
By:	/s/ RICE POWELL
	Name:	Rice Powell
	Title:	Chief Executive Officer and Chairman of the Management Board of the General Partner
By:	/s/ MICHAEL BROSNAN
	Name:	Michael Brosnan
	Title:	Chief Financial Officer and Member of the Management Board of the General Partner

EX-99.1

Exhibit 99.1

Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com

3 May 2017

Fresenius Medical Care delivers strong first quarter 2017

·Strong revenue increase by 14%1 supported by growth in all regions and Care Coordination activities

·Net income1,2 growth of 17% ahead of revenue development

·First quarter performance in line to achieve full year guidance

·Acquisition of majority stake in Cura Group, Australia, completed

Key figures (IFRS)

EUR million	Q1 2017	Q1 2016	growth
Revenue	4,548	3,916	+16	%
Adjusted revenue1	4,448	3,916	+14	%
Operating income (EBIT)	651	497	+31	%
Adjusted operating income (EBIT)1	552	497	+11	%
Net income1	308	213	+45	%
Adjusted net income1,2	249	213	+17	%
Basic earnings per share (in EUR)	1.01	0.70	+44	%

1 Adjusted for the effects of the agreement with United States Departments of Veterans Affairs and Justice on outstanding payments

2 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

1

Rice Powell, Chief Executive Officer of Fresenius Medical Care, stated: “We saw a very positive start to the year. While both our dialysis services and products business showed strong growth, our Care Coordination activities confirmed its high growth potential. We are shaping our activities in this area and expect the profitability to improve in the course of the year. We are clearly on track to deliver on our ambitious targets for 2017.”

Revenue & earnings

Revenue for the company improved by 16% and reached EUR 4,548 million (12% at constant currency), largely driven by strong Health Care Services revenue growth of 19% in North America (15% at constant currency). Total Health Care Services revenue increased by 18% (14% at constant currency) to EUR 3,769 million, while product revenue grew 8% (6% at constant currency) to EUR 779 million. Organic growth3 of 9% for Health Care Services and 5% for the products business confirmed the strong underlying dynamic in the first quarter 2017.

Total operating income (EBIT) increased by 31% to EUR 651 million (margin of 14.3%). This increase was strongly supported by the Dialysis business in North America, the agreement with the United States Departments of Veterans Affairs and Justice and the business growth in Asia Pacific.

Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was EUR 308 million, a very strong increase of 45%. Excluding the agreement with the United States Departments of Veterans Affairs and Justice, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA increased by 17%. Based on a number of approximately 306.2 million shares (weighted average number of shares outstanding), basic earnings per share (EPS) amounted to EUR 1.01, compared to EUR 0.70 for the first quarter of 2016.

Development of Reporting Segments

North America revenue increased by 18% to EUR 3,375 million and corresponds to 74% of total revenue. At constant currency rates growth was at 14%. The Dialysis business grew by 14% (10% at constant currency), Care Coordination increased by 39% (34% at constant currency). The continued progress in Care Coordination was driven by organic growth of 27% and contributed EUR 691 million in revenues. Dialysis Care Services revenue growth was positively influenced by the positive effect from the

3 Adjusted for the effects of the agreement with United States Departments of Veterans Affairs and Justice for outstanding payments

2

agreement with the United States Departments of Veterans Affairs and Justice, a favourable impact from commercial payors and an increased number of treatments. Product revenue increased by 9% (6% at constant currency) due to higher sales of machines and products for peritoneal dialysis.

The substantially improved Dialysis operating income margin of 19.6% (+310 bp compared to Q1 2016) was driven by the agreement with the United States Departments of Veterans Affairs and Justice, a favourable impact from commercial payors, lower costs for health care supplies partially offset by higher personnel expense. The year over year lower margin in the Care Coordination activities was driven by higher bad debt expense, the impact from lower revenue for vascular services and increased costs for pharmacy services, partially offset by earnings recognized from the Bundled Payment for Care Improvement (BPCI) initiative related to hospitalist and intensivist services.

The total operating income of the North America segment was EUR 526 million (+31%), the operating income margin improved to 15.6%. Operating income (EBIT) for the first quarter 2017 excluding the agreement with the Veteran Administration was EUR 427 million, an increase of 6% compared to Q1 2016 (3% at constant currency). Excluding the agreement with the United States Departments of Veterans Affairs and Justice the operating income margin was 13.0%.

EMEA revenue increased by 7% (6% at constant currency) to EUR 614 million, mainly driven by a positive business development in Health Care Services revenue which increased by 11% (9% at constant currency). The increase at constant currency was driven by acquisitions and same-market treatment growth. Dialysis Product revenue grew by 1% to EUR 290 million. Positively influenced by an acquired business, the company generated EUR 21 million of non-dialysis product revenue. Operating income was EUR 114 million in Q1 2017, the operating income margin decreased from 20.6% to 18.7% mainly due to an unfavorable impact from acquisitions, overhead costs and a lower income from equity method investees.

Asia-Pacific revenue grew by 11% (7% at constant currency) to EUR 378 million. In the region Health Care Services generated revenue of EUR 169 million and therewith showed a 4% organic revenue growth. With a growth of 11% (8% constant currency) to EUR 209 million, the product business showed a solid sales performance, mainly driven by higher sales of dialyzers, machines and products for acute care treatments. Operating income increased to EUR 82 million (38%) and was supported by an improved revenue mix and

3

the prior year impact from costs associated with changes in the management board. Operating income margin improved to 21.7% (compared to 17.5% in Q1 2016).

End of April 2017 Fresenius Medical Care successfully closed the acquisition of Cura day hospital group in Australia - the first step into Care Coordination outside the North American market. The transaction is strengthening the Company’s regional footprint by scaling up to around 40 outpatient facilities. The new entity generated EUR 87 million in revenues in the business year 2015/2016. Consolidation effects are already reflected in the given guidance for 2017.

Latin America delivered revenue of EUR 177 million, a significant improvement of 28%. At constant currency rates the business grew by 17%. The growth was mainly driven by reimbursement increases, higher number of treatments and a favorable currency impact. Product revenue grew by 23% based on higher machine sales. Operating income was at EUR 14 million, compared to EUR 10 million in previous year’s Q1. Operating income margin increased to 8.1% in Q1 2017 from 7.0% in Q1 2016.

Net interest expense was EUR 92 million compared to EUR 96 million in the first quarter of 2016. The decrease was driven by the replacement of high interest bearing senior notes repaid in 2016 by debt instruments at lower interest rates partially offset by an increased average debt level. Income tax expense was EUR 182 million for the first quarter of 2017, which translates into an effective tax rate of 32.5%, compared to last year’s Q1 with a tax rate of 31.4%. The increase was primarily driven by a lower portion of tax-free income attributable to non-controlling interests and the agreement with the United States Departments of Veterans Affairs and Justice.

Cash flow

In the first quarter of 2017, the company generated EUR 170 million in net cash provided by operating activities, representing 4% of revenue, compared to EUR 163 million in last year’s Q1. The cash flow was positively influenced by the payment related to the agreement with the United States Departments of Veterans Affairs and Justice, offset by seasonality in invoicing. The seasonality in invoicing will have no meaningful impact on the full year 2017. The number for DSO (days sales outstanding) increased sequentially by 3 days compared to Q4 2016 and reached 73 days.

4

Employees

As of March 31, 2017, Fresenius Medical Care had 110,530 employees (full-time equivalents) worldwide, compared to 104,687 employees at the end of March 2016. This increase was mainly attributable to our continued organic growth and acquired companies.

Outlook 2017 confirmed

Based on the very positive Q1 business development, Fresenius Medical Care confirms its full year outlook 2017. The company expects revenue growth between 8% and 10% at constant currency for fiscal 2017. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to increase by 7% to 9% at constant currency over the previous year. The effects of the agreement with the U.S. Departments of Veterans Affairs and Justice are excluded.

Conference call

Fresenius Medical Care will hold a conference call to discuss the results of the first quarter 2017 on Wednesday, May 3, 2017 at 3.30 p.m. CEDT/ 9.30 a.m. EDT. The company invites investors to follow the live webcast of the call at the company’s website www.freseniusmedicalcare.com in the “Investors/Events” section. A replay will be available shortly after the call.

Please refer to our statement of earnings included at the end of this news and to the attachments as separate excel- and PDF-files for a complete overview of the results for the first quarter 2017.

Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,654 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 310,473 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

5

Fresenius Medical Care - Statement of earnings

in Euro million, except share data, unaudited

	Three months ended March 31,
	2017			2016			Change
Revenue
Health Care Services	3,769			3,199			17.8	%
Health Care Products	779			717			8.5	%
Total revenue	4,548			3,916			16.1	%
Total revenue adjusted1	4,448			3,916			13.6	%
Cost of revenue	2,956			2,622			12.8	%
Gross profit	1,592			1,294			22.9	%
Selling, general and administrative	924			780			18.3	%
Research and development	32			34			-6.6	%
Income from equity method investees	(15		)	(17		)	-11.7	%
Operating income (EBIT)	651			497			31.1	%
Operating income (EBIT) adjusted1	552			497			11.1	%
Interest expense, net	92			96			-2.9	%
Income before taxes	559			401			39.2	%
Income tax expense	182			126			44.2	%
Net income	377			275			36.8	%
Less: Net income attributable to noncontrolling interests	69			62			10.4	%
Net income2	308			213			44.6	%
Net income adjusted1,2	249			213			16.9	%
Operating income (EBIT)	651			497			31.1	%
Depreciation and amortization	190			165			14.9	%
EBITDA	841			662			27.0	%
EBITDA margin	18.5		%	16.9		%
Weighted average number of shares	306,241,321			305,325,185
Basic earnings per share	€	1.01		€	0.70		44.1	%
Basic earnings per ADS	€	0.50		€	0.35		44.1	%
In percent of revenue
Costs of revenue	65.0		%	66.9		%
Gross profit	35.0		%	33.1		%
Operating income (EBIT)	14.3		%	12.7		%
Net income attributable to shareholders of FMC AG & Co. KGaA	6.8		%	5.4		%

1 Adjusted for the effects of the agreement with United States Departments of Veterans Affairs and Justice on outstanding payments

2 Net income attributable to shareholders of FMC AG & Co. KGaA

6

EX-99.2

Exhibit 99.2

Fresenius Medical Care AG & Co. KGaA

COMPLETE OVERVIEW OF THE RESULTS FOR THE FIRST QUARTER 2017

May 3, 2017

Investor Relations

phone: +49 6172 609 2525

fax: +49 6172 609 2301

email: ir@fmc-ag.com

Content:
Statement of earnings	page 2
Segment information	page 3
Balance sheet	page 4
Cash flow	page 5
Revenue development	page 6
Key metrics	page 7
Quality data	page 8
Reconciliation	page 9
Reconciliation one time PY	page 10
Remarks	page 11

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Copyright by Fresenius Medical Care AG & Co. KGaA

1

Statement of earnings

	Three months ended March 31						Change
in € million, except share data, unaudited	2017		2016		Change		at cc
Health Care Services	3,769		3,199		17.8	%	13.8	%
Health Care Products	779		717		8.5	%	5.8	%
Total revenue	4,548		3,916		16.1	%	12.4	%
Costs of revenue	2,956		2,622		12.8	%	8.9	%
Gross profit	1,592		1,294		22.9	%	19.4	%
Selling, general and administrative	924		780		18.3	%	14.7	%
Research and development	32		34		-6.6	%	-8.1	%
Income from equity method investees	(15	)	(17	)	-11.7	%	-11.8	%
Operating income (EBIT)	651		497		31.1	%	27.6	%
Interest income	(29	)	(10	)	185.3	%	186.7	%
Interest expense	121		106		15.0	%	12.7	%
Interest expense, net	92		96		-2.9	%	-5.6	%
Income before taxes	559		401		39.2	%	35.5	%
Income tax expense	182		126		44.2	%	40.5	%
Net income	377		275		36.8	%	33.3	%
Less: Net income attributable to noncontrolling interests	69		62		10.4	%	6.7	%
Net income attributable to shareholders of FMC AG & Co. KGaA	308		213		44.6	%	41.0	%
Operating income (EBIT)	651		497		31.1	%	27.6	%
Depreciation and amortization	190		165		14.9	%	11.3	%
EBITDA	841		662		27.0	%	23.5	%
EBITDA margin	18.5	%	16.9	%
Weighted average number of shares	306,241,321		305,325,185
Basic earnings per share	€ 1.01		€ 0.70		44.1	%	40.6	%
Basic earnings per ADS	€ 0.50		€ 0.35		44.1	%	40.6	%
In percent of revenue
Costs of revenue	65.0	%	66.9	%
Gross profit	35.0	%	33.1	%
Operating income (EBIT)	14.3	%	12.7	%
Net income attributable to shareholders of FMC AG & Co. KGaA	6.8	%	5.4	%

2

Segment information

	Three months ended March 31						Change
unaudited	2017		2016		Change		at cc
Total
Revenue in € million	4,548		3,916		16.1	%	12.4	%
Operating income (EBIT) in € million	651		497		31.1	%	27.6	%
Operating income margin in %	14.3	%	12.7	%
Delivered EBIT in € million	582		435		34.0	%	30.6	%
Days sales outstanding (DSO)	73		74
Employees (full-time equivalents)	110,530		104,687
North America
Revenue in € million	3,375		2,862		17.9	%	13.9	%
Operating income (EBIT) in € million	526		402		30.9	%	26.6	%
Operating income margin in %	15.6	%	14.0	%
Delivered EBIT in € million	459		342		34.5	%	30.2	%
Days sales outstanding (DSO)	60		60
U.S.
Revenue per dialysis treatment in US$	356	1)	348		2.2	%	n.a.
Cost per dialysis treatment in US$	290		281		2.9	%	n.a.
EMEA
Revenue in € million	614		572		7.2	%	6.4	%
Operating income (EBIT) in € million	114		118		-3.0	%	-1.9	%
Operating income margin in %	18.7	%	20.6	%
Delivered EBIT in € million	114		117		-3.2	%	-2.1	%
Days sales outstanding (DSO)	102		104
Asia-Pacific
Revenue in € million	378		340		11.1	%	6.9	%
Operating income (EBIT) in € million	82		59		37.8	%	34.7	%
Operating income margin in %	21.7	%	17.5	%
Delivered EBIT in € million	80		58		38.1	%	35.1	%
Days sales outstanding (DSO)	97		104
Latin America
Revenue in € million	177		139		27.6	%	17.4	%
Operating income (EBIT) in € million	14		10		47.3	%	43.3	%
Operating income margin in %	8.1	%	7.0	%
Delivered EBIT in € million	14		10		47.0	%	43.0	%
Days sales outstanding (DSO)	134		148
Corporate
Revenue in € million	4		3		61.2	%	61.1	%
Operating income (EBIT) in € million	(85	)	(92	)	-7.4	%	-8.2	%
Delivered EBIT in € million	(85	)	(92	)	-7.5	%	-8.3	%

1 Incl. The VA agreement revenue per dialysis treatment was $371.

3

Balance sheet

	March 31		December 31
in € million, except net debt/EBITDA ratio	2017		2016
	(unaudited)		(audited)
Assets
Current assets	7,077		6,884
Goodwill and Intangible assets	13,738		13,759
Other non-current assets	4,965		4,861
Total assets	25,780		25,504
Liabilities and equity
Current liabilities	5,377		5,299
Long-term liabilities	9,105		9,154
Total equity	11,298		11,051
Total liabilities and equity	25,780		25,504
Equity/assets ratio	44	%	43	%
Debt
Short-term debt	697		572
Short-term debt from related parties	119		3
Current portion of long-term debt and capital lease obligations	715		724
Long-term debt and capital lease obligations, less current portion	6,739		6,833
Total debt	8,270		8,132
Cash	671		709
Total net debt	7,599		7,423
Net debt/EBITDA	2.3		2.3

4

Cash flow statement

	Three months ended March 31
in € million, unaudited	2017		2016
Operating activities
Net income	377		275
Depreciation / amortization	190		165
Change in working capital and other non-cash items	(397	)	(277	)
Net cash provided by operating activities	170		163
In percent of revenue	3.7	%	4.2	%
Investing activities
Purchases of property, plant and equipment	(197	)	(227	)
Proceeds from sale of property, plant and equipment	2		4
Capital expenditures, net	(195	)	(223	)
Free cash flow	(25	)	(60	)
In percent of revenue	-0.6	%	-1.5	%
Acquisitions and investments, net of cash acquired, and purchases of intangible assets	(160	)	(83	)
Proceeds from divestitures	—		—
Acquisitions and investments, net of divestitures	(160	)	(83	)
Free cash flow after investing activities	(185	)	(143	)

5

Revenue development

in € million, unaudited	2017	2016	Change		Change at cc		Organic growth		Same market treatment growth1
Three months ended March 31
Total revenue	4,548	3,916	16.1	%	12.4	%	8.4	%
Health Care Services	3,769	3,199	17.8	%	13.8	%	9.2	%	3.0	%
Health Care Products	779	717	8.5	%	5.8	%	4.9	%
North America	3,375	2,862	17.9	%	13.9	%	9.5	%
Health Care Services	3,165	2,671	18.5	%	14.5	%	9.8	%	3.3	%2
Thereof Care Coordination revenue	691	499	38.6	%	33.9	%	27.1	%
Thereof Dialysis Care Services revenue	2,474	2,172	13.9	%	10.1	%	5.7	%	3.3	%2
Health Care Products	210	191	9.3	%	5.6	%	5.6	%
EMEA	614	572	7.2	%	6.4	%	2.3	%
Health Care Services	303	273	10.9	%	9.2	%	3.2	%	3.9	%
Health Care Products	311	299	3.8	%	3.8	%	1.5	%
Thereof Dialysis Products	290	286	1.3	%	1.3	%	1.8	%
Thereof Non-Dialysis Products	21	13	61.8	%	61.8	%	-5.9	%
Asia-Pacific	378	340	11.1	%	6.9	%	6.2	%
Health Care Services	169	153	10.8	%	5.1	%	3.6	%	3.8	%
Health Care Products	209	187	11.4	%	8.4	%	8.4	%
Latin America	177	139	27.6	%	17.4	%	16.7	%
Health Care Services	132	102	29.1	%	21.6	%	20.4	%	2.5	%
Health Care Products	45	37	23.3	%	5.7	%	6.7	%
Corporate	4	3	61.2	%	61.1	%

1 same market treatment growth = organic growth less price effects

2 U.S. (excl. Mexico), same market treatment growth North America: 2.6%

6

Key metrics North America segment

	Three months ended March 31
unaudited	2017		2016		Change		Change at cc
Care Coordination
Revenue in € million	691		499		38.6	%	33.9	%
Operating income (EBIT) in € million	-1		11		-107.6	%	-107.3	%
Operating income margin in %	-0.1	%	2.2	%
Delivered EBIT in € million	-8		3		-342.9	%	-334.7	%
Dialysis
Revenue in € million	2,684		2,363		13.5	%	9.7	%
Operating income (EBIT) in € million	527		391		34.8	%	30.4	%
Operating income margin in %	19.6	%	16.5	%
Delivered EBIT in € million	467		339		38.0	%	33.6	%

Key metrics Care Coordination

	Three months ended March 31
unaudited	2017	2016	Change		Change at cc
North America
Member months under medical cost management1)	155,622	93,375	67	%
Medical cost under management (in € million)1)	1,064	599	78	%	72	%
Care Coordination patient encounters1)	1,608,179	1,307,076	23	%

1) The metrics may be understated due to a physician mapping issue related to the BPCI program within a CMS system which has not yet been resolved. Additionally, data presented for the BPCI and ESCO metrics are subject to finalization by CMS, which may result in changes from previously reported metrics.

Key metrics Dialysis Care Services

	Three months ended March 31, 2017
unaudited	Clinics	Growth in %		De novos	Patients	Growth in %		Treatments
Total	3,654	6	%	19	310,473	6	%	11,744,442
North America	2,323	4	%	11	190,480	4	%	7,246,232
EMEA	722	10	%	4	60,168	9	%	2,271,334
Asia-Pacific	377	17	%	3	29,639	11	%	1,042,046
Latin America	232	2	%	1	30,186	3	%	1,184,830

7

Quality data

	North America		EMEA		Latin America		Asia-Pacific
in % of patients	Q1 2017	Q4 2016	Q1 2017	Q4 2016	Q1 2017	Q4 2016	Q1 2017	Q4 2016
Clinical Performance
Single Pool Kt/v > 1.2	98	98	95	96	92	91	96	97
No catheter (> 90 days)	84	84	81	81	81	82	89	91
Hemoglobin = 10-12 g/dl	73	73	80	78	51	52	59	60
Hemoglobin = 10-13 g/dl	79	79	78	77	67	68	68	68
Albumin > 3.5 g/dl1)	78	78	87	86	90	91	87	89
Phosphate < 5.5 mg/dl	63	64	77	77	74	77	67	72
Calcium = 8.4-10.2 mg/dl	84	84	74	76	75	79	75	75
Hospitalization days	10.0	10.0	7.7	8.0	3.9	3.8	4.0	4.4
Demographics
Average age (in years)	63	63	64	64	59	59	62	65
Average time on dialysis (in years)	4.0	4.0	5.6	5.5	5.3	5.2	4.8	5.1
Average body weight (in kg)	83	83	73	73	68	68	61	61
Prevalence of diabetes (in%)	62	62	32	32	27	22	40	42

1) International standard BCR CRM470

8

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

	Three months ended March 31
in € million, unaudited	2017		2016
Delivered EBIT reconciliation
Total
Operating income (EBIT)	651		497
less noncontrolling interests	(69	)	(62	)
Delivered EBIT	582		435
North America
Operating income (EBIT)	526		402
less noncontrolling interests	(67	)	(60	)
Delivered EBIT	459		342
Care Coordination
Operating income (EBIT)	(1	)	11
less noncontrolling interests	(7	)	(8	)
Delivered EBIT	(8	)	3
Dialysis
Operating income (EBIT)	527		391
less noncontrolling interests	(60	)	(52	)
Delivered EBIT	467		339
EMEA
Operating income (EBIT)	114		118
less noncontrolling interests	(0	)	(1	)
Delivered EBIT	114		117
Asia-Pacific
Operating income (EBIT)	82		59
less noncontrolling interests	(2	)	(1	)
Delivered EBIT	80		58
Latin America
Operating income (EBIT)	14		10
less noncontrolling interests	—		—
Delivered EBIT	14		10
Corporate
Operating income (EBIT)	(85	)	(92	)
less noncontrolling interests	—		—
Delivered EBIT	(85	)	(92	)
Reconciliation of net cash provided by operating activities to EBITDA1)
Total EBITDA	841		662
Interest expense, net	(92	)	(96	)
Income tax expense	(182	)	(126	)
Change in working capital and other non-cash items	(397	)	(277	)
Net cash provided by operating activities	170		163
Annualized EBITDA2)
Operating income (EBIT)	2,558		2,173
Depreciation and amortization	733		656
Non-cash charges	74		51
Annualized EBITDA	3,365		2,880

1) EBITDA is the basis for determining compliance with certain covenants in Fresenius Medical Care’s long-term debt instruments.

2) EBITDA 2017 : including largest acquisitions.

9

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

	Three months ended March 31
in € million, unaudited	2017		2016
Operating performance excluding VA Agreement1
Revenue
Total
Revenue	4,548		3,916
VA Agreement	(100	)
Revenue excluding VA Agreement	4,448		3,916
Health Care Sevices revenue	3,769		3,199
VA Agreement	(100	)
Health Care Services revenue excluding VA Agreement	3,669		3,199
North America
Revenue	3,375		2,862
VA Agreement	(100	)
Revenue excluding VA Agreement	3,275		2,862
Health Care Sevices revenue	3,165		2,671
VA Agreement	(100	)
Health Care Services revenue excluding VA Agreement	3,065		2,671
Dialysis Care Services revenue	2,474		2,172
VA Agreement	(100	)
Dialysis Care Services revenue excluding VA Agreement	2,374		2,172
Operating income (EBIT)
Total
Operating income (EBIT)	651		497
VA Agreement	(99	)
Operating income (EBIT) excluding VA Agreement	552		497
North America
Operating income (EBIT)	526		402
VA Agreement	(99	)
Operating income (EBIT) excluding VA Agreement	427		402
Net income2	308		213
VA Agreement	(59	)
Net income excluding VA Agreement2	249		213

1 Agreement with the United States Departments of Veterans Affairs and Justice

2 attributable to shareholders of FMC AG & Co. KGaA

10

Remarks

cc = Constant Currency. Changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items include the impact of changes in foreign currency exchange rates. We use the non-IFRS financial measure at Constant Exchange Rates or Constant Currency to show changes in our revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items without giving effect to period-to-period currency fluctuations. Under IFRS, amounts received in local (non-euro) currency are translated into euro at the average exchange rate for the period presented. Once we translate the local currency for the Constant Currency, we then calculate the change, as a percentage, of the current period using the prior period exchange rates versus the prior period. This resulting percentage is a non-IFRS measure referring to a change as a percentage at Constant Currency.

We believe that the non-IFRS financial measure Constant Currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on a company’s revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items from period to period. However, we also believe that the usefulness of data on Constant Currency period-over-period changes is subject to limitations, particularly if the currency effects that are eliminated constitute a significant element of our revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA or other items and significantly impact our performance. We therefore limit our use of Constant Currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency into euro. We do not evaluate our results and performance without considering both Constant Currency period-over-period changes in non-IFRS revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items and changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items prepared in accordance with IFRS. We caution the readers of this report to follow a similar approach by considering data on Constant Currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from IFRS measures next to the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items. As the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.

11